NCT05954312 2026-03-18
A First-in-Human (FIH) Study to Evaluate the Safety and Tolerability of VVD-130037 in Participants With Advanced Solid Tumors
Vividion Therapeutics, Inc.
Phase 1 Recruiting
Vividion Therapeutics, Inc.
AbbVie
Astellas Pharma Inc
Ruijin Hospital
Nanjing Leads Biolabs Co.,Ltd
Krystal Biotech, Inc.
Weill Medical College of Cornell University
Genelux Corporation
National University Hospital, Singapore
Ukrainian Society of Clinical Oncology